Yazar "Yılmaz, Yusuf" için listeleme
-
Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action
Kamani, Lubna; Rahat, Adeel; Yılmaz, Yusuf (Kare Publishing, 2024)The term metabolic dysfunction-associated steatotic liver disease (MASLD), which evolved from its predecessor, nonalcoholic fatty liver disease (NAFLD),[1] -
Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology
Ratziu, Vlad; Yılmaz, Yusuf; Lazas, Don; Friedman, Scott L.; Lackner, Caroline; Behling, Cynthia; Cummings, Oscar W.; Chen, Li; Petitjean, Matthieu; Gilgun-Sherki, Yossi; Gorfine, Tali; Kadosh, Shaul; Eyal, Eli; Sanyal, Arun J. (Wolters Kluwer Medknow Publications, 2024)Background and aims: Antifibrotic trials rely on conventional pathology (CP) despite recognized limitations. We compared single fiber digital image analysis (DIA) with CP to quantify the antifibrotic effect of Aramchol, a ... -
Asia-Pacific association for study of liver guidelines on management of ascites in liver disease
Singh, Virendra; De, Arka; Mehtani, Rohit; Angeli, Paolo; Maiwall, Rakhi; Satapathy, Sanjaya; Singal, Ashwini K.; Saraya, Anoop; Sharma, B. C.; Eapen, C. E.; Rao, P. N.; Shukla, Akash; Shalimar; Choudhary, Narendra S.; Alcantara-Payawal, Diana; Arora, Vinod; Aithal, Guru; Kulkarni, Anand; Roy, Akash; Shrestha, Ananta; al Mahtab, Mamun; Niriella, Madunil A.; Siam, Tan Soek; Zhang, Chun-Qing; Huei, Lee Guan; Yu, Ming-Lung; Roberts, Stuart K.; Peng, Cheng-Yuan; Chen, Tao; George, Jacob; Wong, Vincent; Yılmaz, Yusuf; Treeprasertsuk, Sombat; Kurniawan, Juferdy; Kim, Seung Up; Younossi, Zobair M.; Sarin, Shiv Kumar (Springer, 2023)The development of ascites is a landmark event in the natural history of cirrhosis. -
Association of metabolic dysfunction-associated fatty liver disease with cognitive impairment and all-cause dementia: A comprehensive review
Kaya, Eda; Yılmaz, Yusuf (AVES, 2024)Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant public health concern, affecting one-third of the global population and posing a risk for progressive liver disease. MAFLD is characterized by ... -
Brushing your teeth may be good for your liver: Linking oral health to non-alcoholic fatty liver disease
Yılmaz, Yusuf (Elsevier, 2023)he study by Pischke et al. [1], which explores the relationships between non-alcoholic steatohepatitis (NASH) and periodontitis, warrants commendation. The analysis involved 32 patients with NASH and 100 randomly, ... -
Can frequent toothbrushing reduce the risk of cirrhosis among patients with non-alcoholic fatty liver disease? Hints from a registry-based study
Keklikkıran, Çağlayan; Stepanova, Maria; Younossi, Zobair; Yılmaz, Yusuf (Karger, 2023)Introduction: While poor oral hygiene has been previously associated with an increased risk of non-alcoholic fatty liver disease (NAFLD), its association with hepatic fibrosis remains unclear. Here, we sought to analyze ... -
Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
Eriş, Tansu; Hassan, Moomen; Hikal, Yousra; Sawah, Enas; Daneshgar, Fatemeh; Teker, Ayşe Gülşen; Özel, Furkan; Lüleci, Nimet Emel; Kaya, Eda; Yılmaz, Yusuf (Kare Publishing, 2023)Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. Fi-broScan (R) is used for follow-up of fibrosis and steatosis. This single -cen-ter ... -
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma
Adalı, Gupse; Aykut, Hüseyin; Bilgiç, Nermin Mutlu; Yılmaz, Yusuf (Elsevier, 2024)Objective: Chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) are the leading causes of hepatocellular carcinoma (HCC). This study aimed to explore the impact of baseline MASLD ... -
Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: Assessing the relationship with disease severity and fibrosis
Sakallı Kanı, Ayşe; Özercan, Ahmet; Kanı, Haluk Tarık; Eren, Fatih; Sayar, Kemal; Yılmaz, Yusuf (Kare Publishing, 2023)Background and Aim: Our primary objective is to examine the variance in chronotype, night-eating patterns, and sleep quality in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. In ... -
Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry (TM)
Younossi, Zobair M.; Yu, Ming-Lung; Yılmaz, Yusuf; Alswat, Khalid Aida; Buti, Maria; Fernandez, Marlen Ivon Castellanos; Papatheodoridis, Georgios; Hamid, Saeed S.; El-Kassas, Mohamed; Chan, Wah Kheong; Duseja, Ajay K.; Gordon, Stuart C.; Eguchi, Yuichiro; Isakov, Vasily A.; Roberts, Stuart K.; Fan, Jian-Gao; Singal, Ashwani K.; Romero-Gomez, Manuel; Ahmed, Aijaz; Ong, Janus; Lam, Brian P.; Younossi, Issah; Nader, Fatema; Racila, Andrei; Stepanova, Maria; Alqahtani, Saleh (Wiley, 2023)Chronic hepatitis B (CHB) infection is one of the most common causes of cirrhosis and liver cancer worldwide. Our aim was to assess clinical and patient-reported outcome (PRO) profile of CHB patients from different regions ... -
Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
Alqahtani, Saleh A.; Yılmaz, Yusuf; El-Kassas, Mohamed; Alswat, Khalid; Sanai, Faisal; AlZahrani, May; Abaalkhail, Faisal; AlShaikh, Manal; Stepanova, Maria; Younossi, Zobair M. (Wiley, 2024)Patients with chronic liver disease (CLD) experience health-related quality of life (HRQoL) and patient-reported outcomes (PROs) impairments. We assessed and identified predictors of HRQoL and PROs in CLD patients from ... -
Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: Results from a single-center biopsy study
Kaya, Eda; Yılmaz, Yusuf (Wolters Kluwer Medknow Publications, 2024)To the Editor: The nomenclature for steatotic liver disease has been a topic of debate since 2020. The conventional expression, non-alcoholic fatty liver disease (NAFLD), was introduced in 1980 to describe the occurrence ... -
Decoding 17-beta-hydroxysteroid dehydrogenase 13: a multifaceted perspective on its role in hepatic steatosis and associated disorders
Demirtaş, Coşkun Özer; Yılmaz, Yusuf (Xia & He P)Chronic liver disease (CLD) represents a significant global health burden, with hepatic steatosis-associated disorders-such as metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease, and hepatitis ... -
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis
Mozes, Ferenc E.; Lee, Jenny A.; Vali, Yasaman; Selvaraj, Emmanuel A.; Jayaswal, Arjun N. A.; Boursier, Jerome; de Ledinghen, Victor; Lupsor-Platon, Monica; Yılmaz, Yusuf; Chan, Wah-Kheong; Mahadeva, Sanjiv; Karlas, Thomas; Wiegand, Johannes; Tsochatzis, Emmanouil; Liguori, Antonio; Wong, Vincent Wai-Sun; Lee, Dae Ho; Holleboom, Adriaan G.; van Dijk, Anne-Marieke; Mak, Anne Linde; Hagstroem, Hannes; Akbari, Camilla; Hirooka, Masash; Lee, Dong Hyeon; Kim, Won; Okanoue, Takeshi; Shima, Toshihide; Nakajima, Atsushi; Yoneda, Masato; Thuluvath, Paul J.; Li, Feng; Berzigotti, Annalisa; Mendoza, Yuly P.; Noureddin, Mazen; Truong, Emily; Fournier-Poizat, Celine; Geier, Andreas; Tuthill, Theresa; Yunis, Carla; Anstee, Quentin M.; Harrison, Stephen A.; Bossuyt, Patrick M.; Pavlides, Michael (Wiley, 2024)Background & Aims: There is a need to reduce the screen failure rate (SFR) in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials (MASH+F2-3; MASH+F4) and identify people with high-risk MASH (MASH+F2-4) ... -
Editorial: "being normal weight each day keeps NAFLD and fibrosis away"-the importance of reducing cumulative exposure to overweight
Yılmaz, Yusuf (Wiley, 2023)The obesity epidemic is globally driving the increased prevalence of non-alcoholic fatty liver disease (NAFLD), and the vast majority of patients with NAFLD are either overweight or obese. -
Editorial: changes of health-related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD-authors' reply
Yılmaz, Yusuf; Younossi, Zobair (Wiley, 2023)We appreciate the editorial comments by Drs. Sun and Fan about our study assessing the associations of patient-reported outcomes (PROs) and non-invasive tests (NITs) in patients with non-alcoholic fatty liver disease (NAFLD) ... -
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
Sanyal, Arun J.; Foucquier, Julie; Younossi, Zobair M.; Harrison, Stephen A.; Newsome, Philip N.; Chan, Wah-Kheong; Yılmaz, Yusuf; De Ledinghen, Victor; Costentin, Charlotte; Zheng, Ming-Hua; Wai-Sun Wong, Vincent; Elkhashab, Magdy; Huss, Ryan S.; Myers, Robert P.; Roux, Marine; Labourdette, Aymeric; Destro, Marie; Fournier-Poizat, Céline; Miette, Véronique; Sandrin, Laurent; Boursier, Jérôme (Elsevier, 2022)Background & Aims: Currently available non-invasive tests, including fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM by VCTE), are highly effective at excluding advanced fibrosis (AF) (F ≥3) or cirrhosis in ... -
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
Kaya, Eda; Yılmaz, Yusuf (Sage Publications, 2022)Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the most common chronic liver disease worldwide – with an estimated global prevalence of 37%. Different from nonalcoholic fatty liver disease (NAFLD), which ... -
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Hagstrom, Hannes; Adams, Leon A.; Allen, Alina M.; Byrne, Christopher D.; Chang, Yoosoo; Duseja, Ajay; Gronbaek, Henning; Ismail, Mona H.; Jepsen, Peter; Kanwal, Fasiha; Kramer, Jennifer; Loomba, Rohit; Mark, Henry E.; Newsome, Philip N.; Rinella, Mary E.; Rowe, Ian A.; Ryu, Seungho; Sanyal, Arun; Schattenberg, Joern M.; Serper, Marina; Sheron, Nick; Simon, Tracey G.; Spearman, C. Wendy; Tapper, Elliot B.; Villota-Rivas, Marcela; Wild, Sarah H.; Wong, Vincent Wai-Sun; Yılmaz, Yusuf; Zelber-Sagi, Shira; Aberg, Fredrik; Lazarus, Jeffrey V. (Wiley, 2024)Background:Following the adoption of new nomenclature for steatotic liver disease, we aimed to build consensus on the use of International Classification of Diseases codes and recommendations for future research and ... -
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Yip, Terry Cheuk-Fung; Vilar-Gomez, Eduardo; Petta, Salvatore; Yılmaz, Yusuf; Wong, Grace Lai-Hung; Adams, Leon A.; de Ledinghen, Victor; Sookoian, Silvia; Wong, Vincent Wai-Sun (Wiley, 2022)NAFLD has become a major public health problem for more than 2 decades with a growing prevalence in parallel with the epidemic of obesity and type 2 diabetes (T2D). The disease burden of NAFLD differs across geographical ...
